Anaptysbio Stock Debt To Equity
| ANAB Stock | USD 15.51 7.58 32.83% |
AnaptysBio fundamentals help investors to digest information that contributes to AnaptysBio's financial success or failures. It also enables traders to predict the movement of AnaptysBio Stock. The fundamental analysis module provides a way to measure AnaptysBio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AnaptysBio stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.02 | 0.02 |
AnaptysBio | Debt To Equity |
AnaptysBio Company Debt To Equity Analysis
AnaptysBio's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current AnaptysBio Debt To Equity | 0.07 % |
Most of AnaptysBio's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AnaptysBio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AnaptysBio Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for AnaptysBio is extremely important. It helps to project a fair market value of AnaptysBio Stock properly, considering its historical fundamentals such as Debt To Equity. Since AnaptysBio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AnaptysBio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AnaptysBio's interrelated accounts and indicators.
Click cells to compare fundamentals
AnaptysBio Debt To Equity Historical Pattern
Today, most investors in AnaptysBio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AnaptysBio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AnaptysBio debt to equity as a starting point in their analysis.
AnaptysBio Debt To Equity |
| Timeline |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
AnaptysBio Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, AnaptysBio has a Debt To Equity of 0.066%. This is 99.88% lower than that of the Biotechnology sector and 99.66% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.86% higher than that of the company.
AnaptysBio Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AnaptysBio's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AnaptysBio could also be used in its relative valuation, which is a method of valuing AnaptysBio by comparing valuation metrics of similar companies.AnaptysBio is currently under evaluation in debt to equity category among its peers.
AnaptysBio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AnaptysBio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AnaptysBio's managers, analysts, and investors.Environmental | Governance | Social |
AnaptysBio Fundamentals
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 341.31 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 6.71 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 8.95 X | ||||
| Price To Sales | 12.18 X | ||||
| Revenue | 17.16 M | ||||
| Gross Profit | (78.51 M) | ||||
| EBITDA | (143.16 M) | ||||
| Net Income | (163.62 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 17.81 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | 2.77 X | ||||
| Cash Flow From Operations | (120.8 M) | ||||
| Short Ratio | 12.16 X | ||||
| Earnings Per Share | (6.05) X | ||||
| Target Price | 55.3 | ||||
| Number Of Employees | 117 | ||||
| Beta | -0.24 | ||||
| Market Capitalization | 696.21 M | ||||
| Total Asset | 452.39 M | ||||
| Retained Earnings | (614.1 M) | ||||
| Working Capital | 369.39 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
| Net Asset | 452.39 M |
About AnaptysBio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AnaptysBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnaptysBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnaptysBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out AnaptysBio Piotroski F Score and AnaptysBio Altman Z Score analysis. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.